Highly potent p21WAF1-derived peptide inhibitors of CDK-mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A

Journal of Peptide Research

Volumn 60, Issue 5, 2002, Pages 257-270

  Zheleva, D I ^a   McInnes, Campbell ^a   Gavine, A L ^a   Zhelev, N Z ^a   Fischer, P M ^a   Lane, D P ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

Cyclin dependant kinase; Docking; Inhibitor; Recruitment; Substrate

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; HISTIDYLALANYLLYSYLARGINYLARGINYLLEUCYLISOLEUCYLPHENYLALANINE; PEPTIDE FRAGMENT; PROTEIN P21; RECOMBINANT PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; HISTONE; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COMPLEX FORMATION; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE CONTROL; HYDROGEN BOND; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

EUKARYOTA;

AMINO ACID MOTIFS; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; HISTONES; HUMANS; PEPTIDES; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036830109     PISSN: 1397002X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3011.2002.21014.x     Document Type: Article

References (31)

1. Ball, K.L., Lain, S., Fåhraeus, R., Smythe, C. & Lane, D.P. (1997) Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol. 7, 71-80.
2. Warbrick, E., Lane, D.P., Glover, D.M. & Cox, L.S. (1995) A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr. Biol. 5, 275-282.
3. Gulbis, J.M., Kelman, Z., Hurwitz, J., O'Donnell, M. & Kuriyan, J. (1996) Structure of the C-terminal region of p21 (WAF1/CIP1) complexed with human PCNA. Cell 87, 297-306.
4. Zheleva, D.I., Zhelev, N.Z., Fischer, P.M., Duff, S.V. & Lane, D.P. (2000) A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: Affinity, stoichiometry, and thermodynamics. Biochemistry 39, 7388-7397.
5. Xiong, Y., Zhang, H. & Beach, D. (1992) D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71, 504-514.
6. Bonfanti, M., Taverna, S., Salmona, M., D'Incalci, M. & Broggini, M. (1997) p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 57, 144-1446.
7. Mutoh, M., Lung, F.D., Long, Y.Q., Roller, P.P., Sikorski, R.S. & O'Connor, P.M. (1999) A p21 (Waf1/Cip1) carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 59, 3480-34888.
8. Mattock, H., Lane, D.P. & Warbrick, E. (2001) Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. Exp. Cell Res. 265, 234-241.
9. Cayrol, C. & Ducommun, B. (1998) Interaction with cyclin-dependent kinases and PCNA modulates proteasomedependent degradation of p21. Oncogene 19, 2437-2444.
10. Nakanishi, M., Robetorye, R.S., Pereira-Smith, O.M. & Smith, J.R. (1995) The C-terminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J. Biol. Chem. 270, 17060-17063.
11. Chen, Y.-N.P., Sharma, S.K., Ramsey, T.M., Jiang, L., Martin, M.S., Baker, K., Adams, P.D., Bair, K.W. & Kaelin, W.G. (1999) Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl Acad. Sci. USA 96, 4325-4329.
12. WAF1 is mediated by cyclin DI/COK4 inhibition: PCNA binding is not essential. Miami Nature Biotechnol. Short Reports 11, 22.
13. Endicott, J.A., Noble, M.E.M. & Tucker, J.A. (1999) Cyclin-dependent kinases: Inhibition and substrate recognition. Curr. Opin. Struct. Biol. 9, 738-744.
14. Adams, P.D., Sellers, W.R., Sharma, S.K., Wu, A.D., Nalin, C.M. & Kaelin, W.G. Jr (1996) Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16, 6623-6633.
15. Luciani, M.G., Hutchins, J.R.A., Zheleva, D. & Hupp, T.R. (2000) The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J. Mol. Biol. 300, 503-518.
16. Adams, P.D., Li, X., Sellers, W.R., Baker, K.B., Leng, X., Harper, J.W., Taya, Y. & Kaelin, W.G.J. (1999) Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol. Cell. Biol. 19, 1068-1080.
17. Fischer, P.M. & Lane, D.P. (2000) Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. 7, 1213-1245.
18. Rank, K.B., Evans, D.B. & Sharma, S.K. (2000) The N-terminal domains of cyclin-dependent kinase inhibitory proteins block the phosphorylation of cdk2/Cyclin E by the CDK-activating kinase. Biochem. Biophys. Res. Commun. 271, 469-473.
19. Zhang, T. & Prives, C. (2001) Cyclin a-CDK phosphorylation regulates MDM2 protein interactions. J. Biol. Chem. 276, 29702-29710.
20. Russo, A.A., Jeffrey, P.D., Patten, A.K., Massague, J. & Pavletich, N.P. (1996) Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382, 325-331.
21. Brown, N.R., Noble, M.E., Endicott, J.A. & Johnson, L.N. (1999) The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1, 438-443.
22. Lees, J.A. & Weinberg, R.A. (1999) Tossing monkey wrenches into the clock: new ways of treating cancer. Proc. Natl Acad. Sci. USA 96, 4421-4223.
23. Chan, W.C. & White, P.D. (2000) In The Practical Approach Series (Hames B.D., ed.), pp. xx-xx. Oxford University Press, Oxford.
24. Fischer, P.M., Zhelev, N.Z., Wang, S., Melville, J.E., Fåhraeus, R. & Lane, D.P. (1999) Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J. Peptide Res. 55, 163-172.
25. King, D.S., Fields, C.G. & Fields, G.B. (1990) A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int. J. Peptide Protein Res. 36, 255-266.
26. Clackson, T. & Wells, J.A. (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267, 383-386.
27. Clackson, T., Ultsch, M.H., Wells, J.A. & de Vos, A.M. (1998) Structural and functional analysis of the 1:1 growth hormone: Receptor complex reveals the molecular basis for receptor affinity. J. Mol. Biol. 277, 1111-1128.
28. Livnah, O., Stura, E.A., Johnson, D.L., Middleton, S.A., Mulcahy, L.S., Wrighton, N.C., Dower, W.J., Jolliffe, L.K. & Wilson, I.A. (1996) Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 Å. Science 273, 464-471.
29. Harper, J.W., Elledge, S.J., Keyomarsi, K., et al. (1995) Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6, 387-400.
30. Sharma, S.K., Ramsey, T.M., Chen, Y.P., Chen, W., Martin, M.S., Clune, K., Sabio, M. & Bair, K.W. (2001) Identification of E2F-1/Cyclin A antagonists. Bioorg. Med. Chem. Lett. 11, 2449-2452.
31. Wohlschlegel, J.A., Dwyer, B.T., Takeda, D.Y. & Dutta, A. (2001) Mutational analysis of the Cy motif from p21 reveals sequence degeneracy and specificity for different cyclin-dependent kinases. Mol. Cell. Biol. 15, 4868-4874.